Redirecting to http://dergipark.org.tr/_fragment?_hash=iowBTU8gzsWb73BXUYVyJCzqxyp_qUo4VoxHIpuwErQ&_path=id%3D1130758%26_format%3Dhtml%26_locale%3Den%26_controller%3DApp%255CController%255CSite%255CArticleController%253A%253AesiArticleStats.
Research Article
BibTex RIS Cite

Düşük serum meteorin benzeri/subfatin seviyesi, obezite ve insülin direnci ile ilişkilidir

Year 2022, Volume: 7 Issue: 5, 137 - 141, 30.12.2022

Cundullah Cavli , Erhan Önalan , Burkay Yakar , Emir Dönder , İlay Buran , Ebru Önalan

https://doi.org/10.22391/fppc.1130758

Abstract

Giriş: Subfatin olarak da bilinen Meteorin benzeri (Metrnl), obezite ve insülin direncinde rol oynayan ve yeni keşfedilen adiposit kökenli bir adipokindir. Bu çalışma obez hastalarda ve sağlıklı kontrollerde subfatin ile biyokimyasal değerler, demografik veriler ve insülin direnci değerleri arasındaki ilişkiyi araştırmayı amaçlamıştır.

Yöntem: Bu kesitsel çalışmaya cinsiyet ve yaş açısından eşleştirilmiş 41 sağlıklı kontrol ile 59 obez hasta dahil edildi. Subfatin'in (Metrnl) serum seviyelerini ölçmek için bir enzime bağlı immünosorbent tahlili (ELISA) kullanıldı ve Metrnl seviyesinin antropometrik parametreler, HOMA indeksi ve biyokimyasal ölçümlerle korelasyonları değerlendirildi.

Bulgular: Obez hastalarda BKİ (p<0,001), insülin (p=0,002) ve HOMA-IR skoru (p<0,001) düzeyleri kontrollere göre anlamlı derecede yüksekti. Subfatin serum seviyeleri obez hastalarda (1,85 [1,35-5,51] ng/ml) sağlıklı kontrollere (21,82 [12,61-27,76] ng/ml) göre daha düşük bulundu (p<0,001). Subfatin ile yaş (r=-0,250, p=0,012), ağırlık (r=-0,373, p<0,001), BKİ (r=-0,492, p<0,001), HbA1c (r=-0,209, p=0,037), LDL (r=-0,264, p=0,008), HOMA-IR (r=-0,223, p=0,026), glukoz (r=-0,376, p<0,001) arasında negatif anlamlı korelasyon saptandı. Boy (r=0,321, p=0,001) ile subfatin arasında anlamlı pozitif korelasyon saptandı.

Sonuç: Bu sonuçlar, obez hastalarda subfatin düzeylerinin azaldığını göstermektedir. Dolaşımdaki subfatin hormonu miktarları ile yaş, kilo, boy, LDL-kolesterol, glukoz, hbA1c ve HOMA-IR arasında bir ilişki vardır. Subfatin, obezite ve insülin direncinin yeni bir biyobelirteci olabilir.

Anahtar kelimeler: Meteorin benzeri/subfatin, yağlanma, insülin direnci, adipokinler, biyobelirteçler, tip 2 diyabetes mellitus

Keywords

Subfatin/meteorin benzeri obezite insulin direnci biyobelirteçler

Project Number

TF.18.55

References

  • 1. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315. https://doi.org/10.1016/j.biopha.2021.111315
  • 2. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-90. https://doi.org/10.1016/s0140-6736(12)60283-9
  • 3. Kahn SE, Hull RL. Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6. https://doi.org/10.1038/nature05482
  • 4. Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279-91. https://doi.org/10.1016/j.cell.2014.03.065
  • 5. Löffler D, Landgraf K, Rockstroh D, Schwartze JT, Dunzendorfer H, Kiess W, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017;41(1):112-9. https://doi.org/10.1038/ijo.2016.180
  • 6. Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, Puig R, Martínez E, Moreno P, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018;42(4):919-22. https://doi.org/10.1038/ijo.2017.268
  • 7. Ugur K, Erman F, Turkoglu S, Aydin Y, Aksoy A, Lale A, et al. Asprosin. visfatin and subfatin as new biomarkers of obesity and metabolic syndrome. Eur Rev Med Pharmacol Sci. 2022;26(6):2124-33. https://doi.org/10.26355/eurrev_202203_28360
  • 8. El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance. impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract. 2019;150:57-63. https://doi.org/10.1016/j.diabres.2019.02.026
  • 9. Onalan E, Cavlı C, Dogan Y, Onalan E, Gozel N, Buran I, et al. Low serum levels of meteorin-like/subfatin: an indicator of diabetes mellitus and insulin resistance? Endokrynol Pol. 2020;71(5):397-3. https://doi.org/10.5603/ep.a2020.0038
  • 10. Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018;13(9):e0204180. https://doi.org/10.1371/journal.pone.0204180
  • 11. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii. 1-253. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  • 12. Booth A, Magnuson A, Fouts J, Foster MT. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig. 2016;26(1):25-42.
  • 13. Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling. Diabetes. 2015;64(12):4011-22. https://doi.org/10.2337/db15-0274
  • 14. AlKhairi I, Cherian P, Abu-Farha M, Madhoun AA, Nizam R, Melhem M, et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells. 2019;8(10):1283. https://doi.org/10.3390/cells8101283
  • 15. Fadaei R, Dadmanesh M, Moradi N, Ahmadi R, Shokoohi NA, Aghajani H, et al. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules. Arch Physiol Biochem. 2020;126(4):335-40. https://doi.org/10.1080/13813455.2018.1538248
  • 16. Schmid A, Karrasch T, Schäffler A. Meteorin-Like Protein (Metrnl) in Obesity. during Weight Loss and in Adipocyte Differentiation. J Clin Med. 2021;10(19):4338. https://doi.org/10.3390/jcm10194338
  • 17. Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37(5):571-9. https://doi.org/10.1038/aps.2016.9
  • 18. Alizadeh H, Alizadeh A. Association of Meteorin-Like Hormone with insulin resistance and body composition in healthy Iranian adults. Diabetes Metab Syndr. 2020;14(5):881-85. https://doi.org/10.1016/j.dsx.2020.05.031
  • 19. Wang K, Li F, Wang C, Deng Y, Cao Z, Cui Y, et al. Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance. Med Sci Monit. 2019;25:2337-43. https://doi.org/10.12659/msm.915331

Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance

Year 2022, Volume: 7 Issue: 5, 137 - 141, 30.12.2022

Cundullah Cavli , Erhan Önalan , Burkay Yakar , Emir Dönder , İlay Buran , Ebru Önalan

https://doi.org/10.22391/fppc.1130758

Abstract

Introduction: Meteorin-like (Metrnl), also known as subfatin is a newly discovered adipokine of adipocyte origin that may play a role in obesity and insulin resistance. The current study aimed to investigate the association between subfatin and biochemical values, demographic characteristics, and insulin resistance in obese patients and healthy controls.

Methods: This cross-sectional study included 59 obese patients with sex and age-matched group of 41 healthy controls. An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Subfatin (Metrnl), and the correlations of Metrnl level with anthropometric parameters, HOMA index, and biochemical measurements were assessed.

Results: The levels of BMI (p<0.001), insulin (p=0.002), and HOMA-IR score (p<0.001) were significantly higher in obese patients than controls. The serum levels of Subfatin were found to be lower in obese patients (1.85 [1.35–5.51] ng/ml) compared to the healthy controls (21.82 [12.61–27.76] ng/ml) (p<0.001). Subfatin had a significantly negative relationship with age (r =-0.250, p=0.012), weight (r =-0.373, p=0.001), BMI (r =-0.492, p=0.001), HbA1c (r =-0.209, p=0.037), LDL (r =-0.264, p=0.008), HOMA-IR (r =-0.223, p=0.026), and glucose (r =-0.376, p<0.001). There was a significantly positive correlation between subfatin and height (r=0.321, p=0.001).

Conclusion: These results show that levels of subfatin were decreased in obese patients. There is a relationship between circulating amounts of subfatin hormone and age, weight, height, LDL-cholesterol, glucose, hbA1c, and HOMA-IR. Subfatin might be a new biomarker of obesity and insulin resistance.

Keywords: Meteorin-like/subfatin, adiposity, insulin resistance, adipokines, biomarkers, diabetes mellitus type 2

Keywords

meteroin-like/subfatin adiposity insulin resistance adipokines biomarkers diabetes mellitus type 2

Supporting Institution

Firat University Scientific Research Projects

Project Number

TF.18.55

Thanks

We would like to thank Firat University Scientific Research Projects Unit for their financial support.

References

  • 1. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315. https://doi.org/10.1016/j.biopha.2021.111315
  • 2. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-90. https://doi.org/10.1016/s0140-6736(12)60283-9
  • 3. Kahn SE, Hull RL. Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6. https://doi.org/10.1038/nature05482
  • 4. Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279-91. https://doi.org/10.1016/j.cell.2014.03.065
  • 5. Löffler D, Landgraf K, Rockstroh D, Schwartze JT, Dunzendorfer H, Kiess W, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017;41(1):112-9. https://doi.org/10.1038/ijo.2016.180
  • 6. Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, Puig R, Martínez E, Moreno P, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018;42(4):919-22. https://doi.org/10.1038/ijo.2017.268
  • 7. Ugur K, Erman F, Turkoglu S, Aydin Y, Aksoy A, Lale A, et al. Asprosin. visfatin and subfatin as new biomarkers of obesity and metabolic syndrome. Eur Rev Med Pharmacol Sci. 2022;26(6):2124-33. https://doi.org/10.26355/eurrev_202203_28360
  • 8. El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance. impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract. 2019;150:57-63. https://doi.org/10.1016/j.diabres.2019.02.026
  • 9. Onalan E, Cavlı C, Dogan Y, Onalan E, Gozel N, Buran I, et al. Low serum levels of meteorin-like/subfatin: an indicator of diabetes mellitus and insulin resistance? Endokrynol Pol. 2020;71(5):397-3. https://doi.org/10.5603/ep.a2020.0038
  • 10. Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018;13(9):e0204180. https://doi.org/10.1371/journal.pone.0204180
  • 11. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii. 1-253. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  • 12. Booth A, Magnuson A, Fouts J, Foster MT. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig. 2016;26(1):25-42.
  • 13. Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling. Diabetes. 2015;64(12):4011-22. https://doi.org/10.2337/db15-0274
  • 14. AlKhairi I, Cherian P, Abu-Farha M, Madhoun AA, Nizam R, Melhem M, et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells. 2019;8(10):1283. https://doi.org/10.3390/cells8101283
  • 15. Fadaei R, Dadmanesh M, Moradi N, Ahmadi R, Shokoohi NA, Aghajani H, et al. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules. Arch Physiol Biochem. 2020;126(4):335-40. https://doi.org/10.1080/13813455.2018.1538248
  • 16. Schmid A, Karrasch T, Schäffler A. Meteorin-Like Protein (Metrnl) in Obesity. during Weight Loss and in Adipocyte Differentiation. J Clin Med. 2021;10(19):4338. https://doi.org/10.3390/jcm10194338
  • 17. Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37(5):571-9. https://doi.org/10.1038/aps.2016.9
  • 18. Alizadeh H, Alizadeh A. Association of Meteorin-Like Hormone with insulin resistance and body composition in healthy Iranian adults. Diabetes Metab Syndr. 2020;14(5):881-85. https://doi.org/10.1016/j.dsx.2020.05.031
  • 19. Wang K, Li F, Wang C, Deng Y, Cao Z, Cui Y, et al. Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance. Med Sci Monit. 2019;25:2337-43. https://doi.org/10.12659/msm.915331
There are 19 citations in total.

Details

Primary Language English
Subjects ​Internal Diseases
Journal Section Original Research
Authors

Cundullah Cavli 0000-0002-4746-7068

Erhan Önalan 0000-0001-5395-0390

Burkay Yakar 0000-0003-2745-6561

Emir Dönder 0000-0003-2537-6023

İlay Buran 0000-0002-2890-3952

Ebru Önalan 0000-0001-9968-8201

Project Number TF.18.55
Publication Date December 30, 2022
Submission Date June 15, 2022
Acceptance Date November 4, 2022
Published in Issue Year 2022 Volume: 7 Issue: 5

Cite

APA Cavli, C., Önalan, E., Yakar, B., … Dönder, E. (2022). Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance. Family Practice and Palliative Care, 7(5), 137-141. https://doi.org/10.22391/fppc.1130758
AMA Cavli C, Önalan E, Yakar B, Dönder E, Buran İ, Önalan E. Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance. Fam Pract Palliat Care. December 2022;7(5):137-141. doi:10.22391/fppc.1130758
Chicago Cavli, Cundullah, Erhan Önalan, Burkay Yakar, Emir Dönder, İlay Buran, and Ebru Önalan. “Low Serum Levels of Meteorin-Like Subfatin Is Related to Obesity and Insulin Resistance”. Family Practice and Palliative Care 7, no. 5 (December 2022): 137-41. https://doi.org/10.22391/fppc.1130758.
EndNote Cavli C, Önalan E, Yakar B, Dönder E, Buran İ, Önalan E (December 1, 2022) Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance. Family Practice and Palliative Care 7 5 137–141.
IEEE C. Cavli, E. Önalan, B. Yakar, E. Dönder, İ. Buran, and E. Önalan, “Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance”, Fam Pract Palliat Care, vol. 7, no. 5, pp. 137–141, 2022, doi: 10.22391/fppc.1130758.
ISNAD Cavli, Cundullah et al. “Low Serum Levels of Meteorin-Like Subfatin Is Related to Obesity and Insulin Resistance”. Family Practice and Palliative Care 7/5 (December2022), 137-141. https://doi.org/10.22391/fppc.1130758.
JAMA Cavli C, Önalan E, Yakar B, Dönder E, Buran İ, Önalan E. Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance. Fam Pract Palliat Care. 2022;7:137–141.
MLA Cavli, Cundullah et al. “Low Serum Levels of Meteorin-Like Subfatin Is Related to Obesity and Insulin Resistance”. Family Practice and Palliative Care, vol. 7, no. 5, 2022, pp. 137-41, doi:10.22391/fppc.1130758.
Vancouver Cavli C, Önalan E, Yakar B, Dönder E, Buran İ, Önalan E. Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance. Fam Pract Palliat Care. 2022;7(5):137-41.
 Download Cover Image

Family Practice and Palliative Care       ISSN 2458-8865       E-ISSN 2459-1505